home-head3.jpg

NIGONIX’S MISSION IS TO DETECT CANCER EARLY,

WHEN IT CAN BE CURED

Cancer screening test available

for children and AYA 

Generally, the incidence of cancer begins to increase among people in their 50s and becomes higher with advancing age.

However, women in their 20s and 30s sometimes suffer from types of cancer unique to women; and, although small in number,

even children and adolescents/young adults (AYA) are not exempt.

A cancer screening test is an alien concept for young persons.

However, we believe, N-NOSE, a simple, painless urine test, suitable as a cancer test for all generations including children.

 

We see a future in which children will take regular cancer screening tests to detect pre-symptomatic tumors.

We offer the nematode cancer test in anticipation of this becoming the norm.

Secondary screening (Identification of cancer types)

Comprehensive examination (diagnosis based on histological images)

4

Diagnosis by a phisican

Diagnosis

1

Primary screening

(Cancer risk)

2

3

Cancer screening test for everyone

Marker tests under

development

Other diagnostic imaging

(CR, MRI, ultrasound, and endoscopy)

GLOBAL PROBLEM:

CANCER INCIDENCE AND MORTALITY RATE

Cancer is a major cause of death worldwide, and it is estimated that 9.6 million people died from cancer
in 2018.

People often die from cancer because it is too advanced to be treated when detected. However, cancers that are detected early are more likely to respond positively to medical treatment, resulting in low mortality rate. 

Screening is performed to identify people who may have a specific cancer and are in a precancerous state still without clinical manifestations.

 
header-service.jpg

Types of cancer that NIGONiX has been known to be able to detect

Nematodes are known to respond to the types of cancer shown below (as of August 2019):
Stomach, colorectal, lung, breast, pancreatic, liver, prostate, uterine, esophageal, gall bladder, bile duct, kidney, bladder, ovarian, oral/pharyngeal


— 15 types of cancer

FACTS

Why early

matters

Survival rates are higher when cancer is diagnosed at earlier stages. However, effective screening only exists for a few cancer types, and most cancer is detected at later stages, when survival rates are much lower.

Transform cancer care

through early detection

Our mission is to improve and save lives through early cancer detection, and we are developing our test in a rigorous way to deliver our test to patients safely and effectively.

Where hope

meets rigor

We’re unrelenting in the pursuit of our mission and will not stop until we find a better way.
With the best talent in biology,clinical science, bioinformatics, deep learning, and engineering, our goal is to greatly decrease global cancer mortality.

STAY IN TOUCH

Nigonix
ONE JLT Tower 14th floor
Jumeriah Lake Towers ,Dubai, 103805
United Arab Emirates

Disclaimer
This Website contains statements, names and references, but not limited to past or forward-looking events or features.
Potential risks and uncertainties include factors as general usage, implementation or applications restricted by laws and regulations are part of the disclaimers.


 

Copyright 2020 NIGONiX, Inc.